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Abstract 
Background: L-carnitine seems to be able to prevent complications after heart 
surgery using Cardiopulmonary bypass (CPB) and the adverse effects of pump 
usage. This study aimed to evaluates the effects of L-carnitine on cardiac 
biomarkers and operation characteristics after coronary artery bypass graft 
(CABG) surgery. 
Methods and materials: In this randomized triple-blinded, sixty patients 
undergoing elective CABG surgery were divided into three equal groups to 
receive 2gr oral L-carnitine (group A), 5gr oral L-carnitine (group B) and 
placebo (group C) 2 hours before surgery. IL-6, creatinine, and high 
sensitivity C-reactive protein (HS–CRP) levels, CK-MB, cardiac troponin and 
inotrope administration in ICU or after CPB were recorded for all patients at 
baseline levels and at 8 or 24 hours postoperatively. 
Results: There was an evidence of a significant difference in CPK-MB level 
and number of red blood cell packed used in group A was lower than group 
C (p<0.05). The cardiac troponin level 8 hours after surgery significantly 
decreased in two treatment groups in comparison to group C (p<0.05). The 
need for inotropic support after weaning from CPB, in B group was 
statistically higher than C group (p=0.021).  
Conclusion: Although L-carnitine adjunct therapy appears not to be 
associated with IL-6 and HS–CRP levels, it had beneficial effects on cardiac 
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Introduction 
Cardiovascular disease (CVD) is the main cause 
of death in the world (1). It is also one of the most 
important chronic illnesses, which its growing trend 
has direct connection to the development of urban 
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communities, changing dietary patterns and reducing 
physical activity (2). Ischemic heart disease (IHD) 
refers to a partial to complete narrowing or obstruction 
of the coronary arteries following the atherosclerosis, 
spasm or the presence of a clot. In this disease, the 
affected artery cannot supply the requirements of 
myocardial muscle, which results in angina pectoris 
and myocardial infarction (3). 
Coronary artery bypass grafting (CABG) is an 
effective way to reduce or eliminate IHD symptoms. In 
other words, surgical treatment is one of the methods 
for improving the quality of treatment that leads to 
reduced morbidity and mortality (4). Cardiopulmonary 
bypass (CPB) is a safe and effective technique in 
coronary artery bypass surgery, but the harmful effects 
on brain, lungs and heart should not be ignored (5, 6). 
Development of systemic inflammatory response and 
organ dysfunction are the untoward effects of CPB, 
which leads to increased morbidity or even mortality 
after surgery (7). 
Many assessments have shown that interleukin 
6 (IL-6) is one of the most well-described cytokines 
which acts as a pro-inflammatory factor and also plays 
an important role in ischemia-reperfusion injury (8). In 
addition, this multifunctional anti-inflammatory 
cytokine regulates synthesis of acute phase proteins 
such as fibrinogen, C reactive protein and albumin in 
liver (9-13). The assessment and measuring of C-
reactive protein (CRP) using both standard and high-
sensitivity CRP (HS-CRP) assays is becoming popular 
in clinical practice. The recent medical investigations 
also emphasize on the role of HS-CRP in 
cardiovascular disease (CVD) risk stratification and 
treatment decisions (14, 15). In addition, the cardiac 
troponin T is an known diagnostic tool for pathologies 
including myocardial cell necrosis such as acute 
myocardial infarction, unstable angina pectoris 
myocarditis, and the monitoring of reperfusion 
interventions (16, 17). 
L-carnitine is involved in the transport of fatty 
acids to mitochondria and the consequent oxidation. In 
addition, it participates in the removal of mitochondrial 
metabolism products. The lack of L-carnitine or the 
Carnitine-acylcarnitine carrier has a particular adverse 
effect on cardiomyocytes resulting in cardiomyopathy, 
cardiac arrhythmias, or heart failure (18-20). On the 
other hand, investigations have shown that L-carnitine 
can reduce inflammation in patients (21-23). It 
facilitates transfer of fatty acids to the mitochondrial 
matrix and has protective effects on heart(24). 
Therefore, L-carnitine seems to be able to prevent 
complications after heart surgery using CPB and the 
adverse effects of pump usage. 
Despite the technological advancement in 
cardiopulmonary bypass equipment and using much 
anti-inflammatory or immunological therapy, there is 
no specific treatment to eliminate pump complications. 
The aim of this study was evaluation of L-carnitine on 
preventing inflammation after CABG surgery. 
Methods 
Through this randomized triple-blinded clinical 
trial study, 60 CABG surgery patients divided into 
three groups. Two interventions and a control, each 
containing 20 patients. Patients were assigned to each 
group using a table of random numbers. The entry 
criteria were candidates for elective on-pump CABG, 
aged 18-70 years old and known case of mild heart 
failure (EF: 40-50%). 
Patients with history of seizures, epilepsy, 
cerebrovascular disease, liver failure (elevation of liver 
enzymes more than two times of normal), renal failure 
(serum creatinine higher than two times normal), 
receiving non-steroidal anti-inflammatory or 
corticosteroid drugs were excluded. 
Background information such as demographic 
characteristics, history of diseases and any medication 
were basically recorded for all the participants. This 
study was approved by the ethics committee 
institutional review board of the National Research 
Institute of Tuberculosis and Lung disease (NRITLD) 
and Shahid Beheshti University of Medical Sciences. 
The study conducted according to the declaration of 
Helsinki. All participants signed the informed consent 
term. The study was registered in the Iranian registry 
of clinical trials (IRCT2016060528260N1). 
Group A, patients received 2gr oral solution of 
L-carnitine while B group received 5gr of the same 
medication 2 hours before surgery, in addition to 
standard therapy. For control group, placebo was 
administered in liquid form in the same time. All 
patients received the same premedication and 
anesthetic drugs and the surgery was performed by the 
standard on-pump method. After CPB removal, 
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patients received epinephrine if the hemodynamic was 
not acceptable they transferred to the ICU while 
intubated and passed the standard weaning processes. 
To determine the effectiveness of L-carnitine, IL-6 and 
HS–CRP levels were recorded before and 24 hours 
after surgery beside some other clinical parameters. In 
addition, for all patients the elevation of blood 
creatinine kinase-muscle/brain (CK-MB) and cardiac 
troponin were measured 8 hours after surgery. 
Data were analyzed using SPSS software V.24 
(SPSS Inc.), and Microsoft excel. The normality of 
data was verified by the Shapiro-Wilk and 
Kolmogorov-Smirnov tests. The groups were 
compared in the study periods using Student’s t-test 
and Mann-Whitney, if applicable. The differences 
between variables before and after the intervention 
were compared by paired t test or nonparametric 
Wilcoxon signed rank test. Continuous nonparametric 
distributed variables were compared by using the 
Kruskal-Wallis analysis of variance on ranks. Post hoc 
comparisons were performed with the Dunn method 
for all pairwise multiple comparisons (25). Normally 
distributed variables were displayed as mean ± 
standard deviation and non-normally distributed 
variables were presented as frequency (percentage). 
The differences were considered significant at p<0.05. 
Results 
Totally, sixty CABG candidates enrolled in this 
study, 20 in each group (Group A: 2gr L-carnitine, 
Group B: 5gr L-carnitine and Group C: control group). 
There was no significant difference between the groups 
in demographic and clinical characteristics of the 
participants, prior to surgery but aspirin usage (ASA) 
in A group and MI in B group were significantly higher 
(p<0.05; Table 1). 
Our result showed that there was no statistically 
difference between groups regarding surgery and 
anesthesia characteristics. Although the pump time and 
clamp time were lower in C and B groups than other 
two group but these differences were not significant 
(p>0.05).  
The need for inotropic support after weaning 
from CPB in B group was statistically higher than C 
group (p=0.021). In contrast, the number of patients 
receiving inotropes in ICU were the same in all groups 
(p=0.979). 
The number of packed red blood cell units 
which were transfused during surgery in C group was 
significantly higher than A group (p=0.036). However, 
we did not find any significant difference between 
studied groups regarding usage of fresh frozen plasma 
(FFP) and platelet (Plt) unites during and after that in 
ICU. 
The results of these comparisons can be found 
in Table 2. The cardiac troponin level 8 hours after 
surgery was significantly decreased in two treatment 
groups in comparison to C group. Similarly, the level 
of CPK-MB in A group was significantly lower than 
the C group as well as CPK-MB level in A group was 
less than B group (p=0.032 and 0.032, respectively).  
In all participants, although the both duration of 
mechanical ventilation and ICU stay were decreased in 
treatment groups but these reductions did not show any 
statistical evidence of correlation regarding the clinical 
interventions with group C (p>0.05). 
Further analysis showed that changes in 
creatinine, IL-6, HS–CRP and serum creatinine level 
before and after surgery were not statistically different 
between groups (p=0.493).  
Some complications such as atrial fibrillation 
(AF), myocardial infarction (MI), agitation and 
atelectasis were registered during first 24 hours after 
surgery. The results demonstrated no statistical 
difference between groups in this view (p>0.05). The 
detail of biomarkers level and ICU characteristics are 
described in table 3. 
Discussion 
During the last decades, the mortality associated 
with isolated CABG surgery has been decreased (26-
28). However, myocardial injury is still a significant 
issue in patients undergoing CABG (29). Carnitine 
deficiency is one of the most important causes of 
impaired metabolism, which mainly results in 
cardiomyopathy. Hence, carnitine administration as a 
treatment factor for the deficiency is supported (29-
32). This investigation was designed to assess possible 
beneficial effects of two doses of oral solution of 
carnitine supplementation (2gr, 5gr and control 
groups) on postoperative cardiac function and 
metabolism in patients undergoing CABG. 
Recent findings have revealed that possible 
mechanisms responsible for the observed influence of 
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L-carnitine in MI are multifactorial. L-carnitine may 
improve mitochondrial energy metabolism in heart by 
facilitating the transport of long-chain fatty acids from 
cytosol to mitochondrial matrix, reducing ischemia 
induced by long-chain fatty acid concentrations, and 
replenishing depleted carnitine concentrations seen in 
ischemic, infarcted, and failing myocardium (33-39). 
Therewith, L-carnitine have beneficial effects on left 
ventricular remodeling which accompanied by a 
significant reduction in left ventricular volumes after 
MI (30). Multiple clinical trials showed that L-
carnitine reduced infarct size leading to a greater 
degree of myocardial salvage (40-42). Lack of 
carnitine is the main cause of impaired metabolism, 
Table 1: Baseline and demographic characteristics. 
 Total Group A, n=20 Group B, n=20 Control, n=20 P value# 
Age-years 60.2 ± 11.2 59.7 ± 11.9 58 ± 13.8 63 ± 6.4 0.88 
Gender (Male) 50 (83.3%) 16 (80%) 18 (90%) 16 (80%) 0.64 
BMI (kg/m2) 26.6 ± 3.5 26.7 ± 3.9 26 ± 3.7 26.9 ± 3.6 0.84 
EF-% 47.4 ± 11.2 50.9 ± 67 46 ± 13.1 45.2 ± 12.6 0.54 
Body Surface Area (m2) 1.8 ± 0.2 1.8 ± 0.2 1.9 ± 0.1 1.8 ± 0.2 0.38 
CVA–no (%) 1 (5%) 0 0 1 0.88 
Diabetes mellitus–no (%) 34 (56.6%) 8 (40%) 12 (60%) 14 (70%) 0.31 
Hypertension–no (%) 41 (68.3%) 10 (50%) 16 (80%) 15 (75%) 0.13 
Hyperlipidemia–no (%) 30 (50%) 6 (30%) 12 (60%) 12 (60%) 0.11 
Opium abuse rate (%) 13 (21.6%) 3 (15%) 4 (20%) 6 (30%) 0.66 
MI (%) 6 (10%) 2 (10%) 4 (20%) 0 0.02 
Aspirin (%) 66 ± 9 65 ± 11 71 ± 12 ** 64 ± 8 0.002 
Cigarette Smoking–no (%) 27 (45%) 11 (55%) 8 (40%) 8 (40%) 0.7 
 
Table 2: Operation characteristics and blood products consumption. 
 Group A, n=20 Group B, n=20 Group C, n=20 P value# 
Anesthesia duration-hour 4.85 ± 1.22 4.77 ± 0.84 5.44 ± 1.34 0.374 
Pump time- minute 117.87 ± 45.1 121.33 ± 34. 7 116 ± 28.93 0.981 
Clamp time- minute 71.73 ± 26.08 62.62 ± 21.73 64.8 ± 18.23 0.374 
Inotrope after CPB –no (%) 17 (86.7) 19 (93.3)** 15 (73.3) 0.024 
Inotrope in ICU –no (%) 11 (55) 11 (55) 11 (55) 0.979 
OR Packed Cell -unit 0.73 ± 1.2* 0.8 ± 0.86 1.6 ± 0.91 0.028 
O.R.FFP-unit 0.2 ± 0.56 0.33 ± 0.72 0.67 ± 0.9 0.208 
ICU Packed Cell-unit 0.93 ± 1.33 1.13 ± 1.59 0.33 ± 1.047 0.053 
ICU.FFP-unit 0.4 ± 1.12 0.6 ± 1.18 0.7 ± 1.2 0.586 
OR Plt-unit 0 0 0 - 
ICU Plt-unit 0 0.2 ± 0.77 0 0.38 
*P<0.05 Group A vs. Group C; **P<0.05 Group B vs. Group C; ***P<0.05 Group A vs. Group B; P value # Kruskal–Wallis 
between-group 
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which commonly results in cardiomyopathy (30). 
L-carnitine has been investigated as one of the 
several agents which is effective in prevention of the 
clinical complications associated with ischemia-
reperfusion injury during cardiac surgery (43). The 
results of our study revealed that treatment with L-
carnitine had significant effects on the levels of CK-
MB, use of inotrope after CPB, cardiac troponin and 
intraoperative packed cell transfusion in patients 
undergoing CABG surgery (p<0.05). Although there 
was a reduction in mechanical ventilation time and 
ICU stay in treatment groups, this decline was not 
significant (p>0.05), which could partly be explained 
by the small sample size in our study. On the other 
hand, L-carnitine did not have any effect on 
inflammatory markers levels (IL-6 and HS–CRP). 
Similarity, inotrope in ICU did not change by taking L-
carnitine. By comparison, neither creatinine level 
(p=0.49) nor mechanical ventilation and ICU duration 
(p=0.051) were significantly associated with receiving 
treatment. Although the reduction of length of ICU 
stay and mechanical ventilation time was not 
statistically significant, but they are clinically 
important which play a vital role in the survival or post-
operative complications. Indeed, L-carnitine groups 
had shorter ICU stay and mechanical ventilation time 
than control group which are the utmost important 
indicators for cost estimation in ICU setting (44).  
According to the investigations, 
pharmacological therapy in combination with 
reperfusion can attenuate myocardial dysfunction 
associated with acute coronary syndrome (45, 46). It 
seems that, in patients who suspected to acute 
myocardial infarction, oral L-carnitine 
supplementation could decrease the infarct size and 
cardiac biomarkers. In fact, L-carnitine 
supplementation prevents ventricular enlargement and 
ventricular dysfunction, and even diminished total 
cardiac events including cardiac deaths and nonfatal 
infarction (42). The present study has demonstrated 
that the addition of L-carnitine to standard therapy in 
CABG patients before surgery has beneficial effects, 
which the troponin level in treatment groups, verified 
this result. In addition, the packed red blood cell usage 
that transfused during surgery in C group was 
significantly higher than B group (p=0.036) which may 
be related to higher clamp time in this group. In the 
other words, the present study has demonstrated that 
Table 3: Biomarkers level and other ICU characteristics. 
 Group A, n=20 Group B, n=20 Control, n=20 P value 
Mechanical ventilation duration-hour 15.7 ± 15.2 13.7 ± 6.7 14.2 ± 6.8 0.051 
Cardiac Troponin 0.56 ± 0.83* 0.41 ± 0.92** 1.94 ± 2.63 0.049 
Serum creatine phosphokinase (CPK_MB) 55.13 ± 33.5* 67.8 ± 32.4*** 64.87 ± 26.7 0.002 
HS– CRP – before- mg/l 6.58 ± 7.14 6.38 ± 6 7.9 ± 6.4 0.247 
HS– CRP-after - mg/l 18.9 ± 0.0001 16.4 ± 5.2 18.5 ± 1.5 0.138 
IL 6 –before- pg/ml 1.76 ± 2.83 4.24 ± 6.07 1.02 ± 0.077 0.648 
IL 6 –after- pg/ml 33.7 ± 22.7 34.7 ± 30.4 30.4 ± 20.57 0.789 
Serum Creatinine level-before Mg/dl 1.17 ± 0.4 1.13 ± 0.53 1.19 ± 0.17 0.999 
Serum Creatinine level-after- Mg/dl 1.6 ± 0.8 1.6 ± 0.7 1.6 ± 0.3 0.493 
Atrial fibrillation (AF) 3 (15) 2 (10) 2 (10) 0.848 
Post Op. MI - 1 (5) - 0.368 
Agitation - 2 (10) - 0.129 
Atelectasis - - 1 (5) 0.368 
ICU stay-day 3.1 ± 1.1 3.3 ± 0.8 4.2 ±1.1 0.051 
Plus-minus values are means ± SD. CPB cardiopulmonary bypass. HS– CRP 
*P<0.05 Group A vs. Group C; **P<0.05 Group B vs. Group C; ***P<0.05 Group A vs. Group B; P value # Kruskal–Wallis 
between-group 
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the addition of oral L-carnitine to standard treatment 
before intervention reduces the levels of troponin and 
packed red blood cell usage, indicating diminished 
myocardial injuries which these findings supported by 
previous findings in the literature (47).  
Myocardial ischemia as a metabolic 
phenomenon in CABG patients leads to stress imposed 
during CPB, obligatory interruption of coronary blood 
flow during aortic cross clamp and reperfusion after 
aortic cross clamp release. These side effects affect 
patients in the form of hemodynamic instability, 
arrhythmias and even greater use of inotropes. In fact, 
the lack of oxygen which imposed during CPB induce 
some serious side effects such as increased need of 
inotropes, prolonged mechanical ventilation, 
prolonged ICU stay and even increase in the morbidity 
and mortality rate of patients. According to this study, 
the two treated groups with L-carnitine had higher 
usage of inotrope but there was a significant difference 
between the B and C groups in terms of receiving 
inotropes following surgery (p=0.021). In fact, patients 
with a higher pump time showed more needs for taking 
inotropes and higher inotrope use following the 
surgery.  
In another view, supplementation with oral L-
carnitine reduces superoxide production (48) and the 
function of endothelial nitric oxide-synthase (NO) 
(49). Indeed, L-carnitine enters the NO production 
cycle and increase the rate of NO. Therefore, the 
dilated vessels cause a drop in blood pressure (47). In 
our patients, this reduction was temporary because the 
blood pressure reduction was not observed in ICU 
patients. Since, the pulse pressure and thereby blood 
pressure can be used for decision about early treatment 
strategy especially associated with usage of inotropic 
agents, Therefore blood pressure reduction leads to 
more inotrope administration in CABG patients (50). 
Randomized trials have revealed that patients 
with acute coronary syndrome who received L-
carnitine as an adjunct therapy had improved outcomes 
comparing to patients who were not treated (51-53). 
Treatment with L-carnitine leads to a significant 
reduction of these enzymes that is attributable to a 
decrease in oxidative stress and stabilization of 
cardiomyocyte cell membranes. The infarct size, 
cardiac mortality rates and in-hospital events would 
decrease if the occluded coronary arteries were rapidly 
reperfused. Howsoever, other degrees of reperfusion 
injuries have been stated following the intervention. 
These injuries result in an increase in plasma CK-MB 
and troponin levels which this increment in myocardial 
markers is strongly related to adverse clinical 
outcomes after intervention (54). The pharmacological 
treatment in addition to reperfusion therapy can 
attenuate myocardial dysfunction associated with acute 
coronary syndrome (45-47, 54). The current study has 
represented that the addition of L-carnitine (dosage 
2gr) two hours before surgery can reduce the levels of 
CK-MB and troponin which indicate a reduction in 
myocardial injuries. The above data are consistent with 
previous findings (47, 55). Current studies confirmed 
that the cardiac troponins are considered as offering the 
highest diagnostic and prognostic value (56). On the 
other hand, these markers can be used for the 
prediction of future left ventricular dysfunction. They 
can be used for early detection of necrosis, even prior 
to significant increase in the levels of CK-MB (57, 58). 
The limitation of this assessment is related to the 
small sample size in each group which seems has a 
significant impact on the results. Therefore, larger 
samples need to be further investigated to confirm our 
preliminary results. We would recommend conducting 
similar trials with larger sample sizes and different 
dosage of L-carnitine to investigate cardiac and 
inflammation biomarkers. 
Conclusion 
Our results demonstrated that among mild heart 
failure patients undergoing CABG surgery, oral L-
carnitine 2 hours before surgery reduced cardiac 
troponin and CK-MB as biomarkers of cardiac injury, 
whereas it did not have any impact on clinical 
parameters. 
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